JP2018070524A - Epidermal cell activator - Google Patents
Epidermal cell activator Download PDFInfo
- Publication number
- JP2018070524A JP2018070524A JP2016213669A JP2016213669A JP2018070524A JP 2018070524 A JP2018070524 A JP 2018070524A JP 2016213669 A JP2016213669 A JP 2016213669A JP 2016213669 A JP2016213669 A JP 2016213669A JP 2018070524 A JP2018070524 A JP 2018070524A
- Authority
- JP
- Japan
- Prior art keywords
- epidermal cell
- extract
- growth factor
- cell growth
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、ムラサキ抽出物、カノコソウ抽出物から選択される１種又は２種を有効成分とする表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤に関する。 The present invention relates to an epidermal cell activator, an epidermal cell growth factor production promoter, and an epidermal cell growth factor receptor production promoter comprising one or two selected from Murasaki extract and valerian extract as active ingredients.
顔や背中や手足などの紫外線に暴露された部分では老化が進み、局部的な色素沈着、いわゆる「シミ」が形成されてくる。シミの形成メカニズムとしては、紫外線や老化などの刺激によるメラニン生成の亢進と転送されたメラニンの排泄のバランスが崩れたものがシミとなって現れてくると言われている。そこで、美白剤に応用されるアプローチとしては、亢進されたメラニン生成を抑える手法と後退したメラニン排泄を回復させる方法が考えられる。これまでに前者のメラニン生成を抑える美白剤の研究は多数なされてきたが、後者のメラニン排泄を回復、促進させる美白剤の研究はあまり行われてこなかった（非特許文献１）。 In areas exposed to ultraviolet rays, such as the face, back and limbs, aging progresses and local pigmentation, so-called “stains” are formed. As a mechanism of the formation of spots, it is said that an increase in melanin production caused by stimulation such as ultraviolet rays and aging and the balance of excretion of transferred melanin are lost appear as spots. Therefore, as an approach applied to the whitening agent, a method of suppressing the enhanced melanin production and a method of recovering the backward melanin excretion can be considered. Many studies on the whitening agent for suppressing the former melanin production have been made so far, but there has not been much research on the whitening agent for recovering and promoting the latter melanin excretion (Non-patent Document 1).
かかる老化症状を防止するため、表皮細胞成長因子（ＥＧＦ）の産生を促進する成分として、ゴマの抽出物、ジオウの抽出物、モモの抽出物、カンゾウの抽出物、ドクダミの抽出物、サボテンの抽出物、コムギ胚芽の抽出物、キャッツクローの抽出物、シソの抽出物、ビワの抽出物が知られている（特許文献１）。 In order to prevent such aging symptoms, as an ingredient that promotes the production of epidermal cell growth factor (EGF), sesame extract, diou extract, peach extract, licorice extract, dokudami extract, cactus extract An extract, an extract of wheat germ, an extract of cat's claw, an extract of perilla and an extract of loquat are known (Patent Document 1).
また、表皮細胞成長因子は、その受容体（表皮細胞成長因子受容体、ＥＧＦＲ）によって細胞内に取り込まれて初めてその効果を発揮することが知られている（特許文献２）。 In addition, it is known that epidermal cell growth factor exhibits its effect only when it is taken into cells by its receptor (epidermal growth factor receptor, EGFR) (Patent Document 2).
これまで、表皮細胞成長（ＥＧＦ）産生促進作用と、表皮細胞成長促進因子受容体（ＥＧＦＲ）産生促進作用を併せ持つ成分に関する研究はなされてこなかった。ＥＧＦ産生促進作用とＥＧＦＲ産生促進作用を兼ね備えることにより、老化等により引き起こされた表皮細胞のターンオーバーを活性化し、くすみや皮膚老化状態を予防する老化防止効果及び美肌効果を発現し、皮膚を健やかに保つことのできる、表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤、を提供することを課題とする。 So far, there has been no research on components having both an epidermal cell growth (EGF) production promoting action and an epidermal cell growth promoting factor receptor (EGFR) production promoting action. By combining EGF production promoting action and EGFR production promoting action, it activates the turnover of epidermis cells caused by aging, etc., expresses anti-aging effect and skin-beautifying effect to prevent dullness and skin aging state, and keeps skin healthy It is an object of the present invention to provide an epidermal cell activator, an epidermal growth factor production promoter, and an epidermal growth factor receptor production promoter that can be kept at a low level.
本発明は、ムラサキ抽出物、カノコソウ抽出物から選択される１種又は２種を有効成分とする表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤、を提供する。 The present invention provides an epidermal cell activator, an epidermal cell growth factor production promoter, and an epidermal cell growth factor receptor production promoter comprising one or two species selected from purple extract and valerian extract as active ingredients. To do.
ムラサキ抽出物、カノコソウ抽出物は、高い表皮細胞賦活効果、表皮細胞成長因子産生促進効果、表皮細胞成長因子受容体産生促進効果を発揮し、くすみや皮膚老化状態を予防する老化防止作用及び美肌作用を発現し、皮膚を健やかに保つことができる。 Murasaki extract and valerian extract exhibit high epidermal cell activation effect, epidermal cell growth factor production promoting effect, epidermal cell growth factor receptor production promoting effect, anti-aging action and skin beautifying action to prevent dullness and skin aging condition And can keep the skin healthy.
以下本発明を実施するための形態を説明する。 Hereinafter, modes for carrying out the present invention will be described.
本発明で使用するムラサキ抽出物は、ムラサキ（Lithospermum officinale）の根を用いる。 As the purple extract used in the present invention, purple root (Lithospermum officinale) roots are used.
本発明で使用するカノコソウ抽出物は、カノコソウ（Valeriana fauriei）の、葉、茎、花、根等の各部位および全草を用いることができるが、根、根茎を用いることが好ましい。 As the valerian extract used in the present invention, leaves, stems, flowers, roots and all parts of valerian (Valeriana fauriei) and whole plants can be used, but roots and rhizomes are preferably used.
本発明において、上記各植物抽出物は生のまま抽出に供してもよいが、抽出効率を考えると、細切，乾燥，粉砕等の処理を行った後に抽出を行うことが好ましい。抽出は、抽出溶媒に浸漬して行う。抽出効率を上げるため撹拌を行ったり、抽出溶媒中でホモジナイズしてもよい。抽出温度としては、５℃程度から抽出溶媒の沸点以下の温度とするのが適切である。抽出時間は抽出溶媒の種類や抽出温度によっても異なるが、４時間〜１４日間程度とするのが適切である。 In the present invention, each plant extract may be subjected to extraction as it is, but considering the extraction efficiency, it is preferable to perform extraction after processing such as shredding, drying, and pulverization. Extraction is performed by immersing in an extraction solvent. In order to increase the extraction efficiency, stirring may be performed, or homogenization may be performed in an extraction solvent. The extraction temperature is suitably about 5 ° C. to the boiling point of the extraction solvent. The extraction time varies depending on the type of extraction solvent and the extraction temperature, but is suitably about 4 hours to 14 days.
抽出溶媒としては、水の他、メタノール，エタノール，プロパノール，イソプロパノール等の低級アルコール、1,3-ブチレングリコール，プロピレングリコール，ジプロピレングリコール，グリセリン等の多価アルコール、エチルエーテル，プロピルエーテル等のエーテル類、酢酸エチル，酢酸ブチル等のエステル類、アセトン，エチルメチルケトン等のケトン類などの極性有機溶媒を用いることができ、これらより１種又は２種以上を選択して用いる。また、生理食塩水，リン酸緩衝液，リン酸緩衝生理食塩水等を用いてもよい。 Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin, and ethers such as ethyl ether and propyl ether. , Polar organic solvents such as esters such as ethyl acetate and butyl acetate, and ketones such as acetone and ethyl methyl ketone can be used, and one or more of these are selected and used. Further, physiological saline, phosphate buffer, phosphate buffered saline, or the like may be used.
上記植物の上記溶媒による抽出物は、そのままでも本発明に係る組成物に含有させることができるが、濃縮，乾固したものを水や極性溶媒に再度溶解したり、或いはそれらの皮膚生理機能向上作用を損なわない範囲で脱色，脱臭，脱塩等の精製処理を行ったり、カラムクロマトグラフィーによる分画処理を行った後に用いてもよい。また保存のため、精製処理の後凍結乾燥し、用時に溶媒に溶解して用いることもできる。また、リポソーム等のベシクルやマイクロカプセル等に内包させて用いることもできる。 The extract of the above-mentioned plant by the above-mentioned solvent can be contained in the composition according to the present invention as it is, but the concentrated and dried solid can be dissolved again in water or a polar solvent, or their skin physiological functions can be improved. It may be used after performing purification treatment such as decolorization, deodorization, desalting or the like within a range not impairing the action, or after fractionation treatment by column chromatography. For storage, it can be freeze-dried after purification and dissolved in a solvent before use. It can also be used by encapsulating in vesicles such as liposomes or microcapsules.
特にリポソーム等のベシクルやマイクロカプセル等に内包させて用いることにより、経皮吸収が高まり、より高い効果を発揮する。 In particular, by being encapsulated in vesicles such as liposomes or microcapsules, percutaneous absorption is enhanced and higher effects are exhibited.
ムラサキ抽出物、カノコソウ抽出物から選択される１種又は２種は、優れた表皮細胞賦活効果、表皮細胞成長因子産生促進効果、表皮細胞成長因子受容体産生促進効果を有し、表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤として利用することができる。 One or two selected from Murasaki extract and valerian extract have excellent epidermal cell activation effect, epidermal cell growth factor production promoting effect, epidermal cell growth factor receptor production promoting effect, and epidermal cell activator It can be used as an epidermal cell growth factor production promoter and epidermal cell growth factor receptor production promoter.
ムラサキ抽出物、カノコソウ抽出物から選択される１種又は２種を含有することを特徴とする表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤は、単独でも使用することができるが、表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤として医薬品、医薬部外品、飲食品、化粧品などの種々の組成物に配合することにより、表皮細胞賦活作用、表皮細胞成長因子産生促進作用、表皮細胞成長因子受容体産生促進作用を有する組成物を得ることができる。 Epidermal cell activator, epidermal cell growth factor production promoter, epidermal cell growth factor receptor production promoter characterized by containing one or two selected from Murasaki extract and valerian extract, Although it can be used, it is incorporated into various compositions such as pharmaceuticals, quasi-drugs, foods and drinks, and cosmetics as epidermal cell activators, epidermal growth factor production promoters, and epidermal cell growth factor receptor production promoters. Thus, a composition having an epidermal cell activation effect, an epidermal growth factor production promoting effect, and an epidermal growth factor receptor production promoting effect can be obtained.
ムラサキ抽出物、カノコソウ抽出物から選択される１種又は２種を含有することを特徴とする表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤は、その形態およびその他成分の配合の有無等については、なんら制限されない。形態については、液状、ペースト状、ゲル状、固体状、粉末状等の任意の形態を、その用途等に応じて選択でき、その形態とするために必要なビヒクル（賦形剤）、溶剤、その他の一般的な添加剤（酸化防止剤、着色剤、分散剤等）を任意に含むことができる。 An epidermal cell activator, an epidermal cell growth factor production promoter, and an epidermal cell growth factor receptor production promoter characterized by containing one or two species selected from Murasaki extract and valerian extract There are no restrictions on the presence or absence of other ingredients. As for the form, any form such as liquid, paste, gel, solid, powder, etc. can be selected according to its use and the like, vehicle (excipient), solvent, Other general additives (antioxidants, colorants, dispersants, etc.) can optionally be included.
ムラサキ抽出物、カノコソウ抽出物から選択される１種又は２種を含有することを特徴とする表皮細胞賦活剤、表皮細胞成長因子産生促進剤、表皮細胞成長因子受容体産生促進剤を配合する組成物は、任意の剤型をとることができる。組成物が皮膚化粧料、毛髪用化粧料、洗浄料等の場合には、ローションなどの可溶化系やカラミンローション等の分散系、クリームや乳液などの乳化系として提供することができる。さらに、噴射剤と共に充填するエアゾール形態、軟膏剤、パップ剤などの種々の剤型で提供することができる。 Composition comprising an epidermal cell activator, an epidermal cell growth factor production promoter, and an epidermal cell growth factor receptor production promoter, characterized by containing one or two selected from Murasaki extract and valerian extract Things can take any dosage form. When the composition is a skin cosmetic, a hair cosmetic, a detergent, etc., it can be provided as a solubilizing system such as lotion, a dispersion system such as calamine lotion, or an emulsifying system such as cream or emulsion. Furthermore, it can provide with various dosage forms, such as an aerosol form filled with a propellant, an ointment, a poultice.
具体的には、乳液、クリーム、ローション、化粧水、パック、美容液、洗浄料、メイクアップ化粧料等の各種化粧料；液剤、軟膏、粉末、顆粒、エアゾール剤、貼付剤、パップ剤等の様々な形態の化粧料、医薬部外品や外用医薬品などが例示できる。 Specifically, various cosmetics such as emulsions, creams, lotions, lotions, packs, cosmetic liquids, cleaning agents, makeup cosmetics, etc .; liquids, ointments, powders, granules, aerosols, patches, poultices, etc. Various forms of cosmetics, quasi drugs, topical medicines, and the like can be exemplified.
また、経口用医薬品等の場合には、ドリンク剤・点滴剤などの液剤、ガム・飴のような固形剤、カプセル、粉末、顆粒、錠剤などの一般的な剤型とすることができる。 In the case of oral pharmaceuticals, etc., general dosage forms such as liquid preparations such as drinks and infusions, solid preparations such as gums and candy, capsules, powders, granules and tablets can be used.
ムラサキ抽出物、カノコソウ抽出物から選択される１種又は２種を含有することを特徴とするムラサキ抽出物、カノコソウ抽出物から選択される１種又は２種を配合する組成物には、これらの他に、その用途と必要に応じて、医薬品、医薬部外品、皮膚化粧料、毛髪用化粧料、洗浄料、および経口用医薬品等に通常配合される任意の成分、例えば水、油性成分、保湿剤、粉体、色素、乳化剤、可溶化剤、ゲル化剤、洗浄剤、紫外線吸収剤、抗炎症剤、増粘剤、ｐＨ調整剤、キレート剤、薬剤（薬効成分）、香料、樹脂、防菌防かび剤、抗酸化剤、アルコール類等を適宜配合することができる。さらに、本発明の効果を損なわない範囲において、他の保湿剤、抗老化剤、美白剤、抗酸化剤および痩身剤あるいは各種植物／菌類またはその抽出物との併用も可能である。 The composition containing one or two selected from the Murasaki extract or the valerian extract, characterized by containing one or two selected from the Murasaki extract or the valerian extract. In addition, any component that is usually blended in pharmaceuticals, quasi-drugs, skin cosmetics, hair cosmetics, cleansing agents, oral pharmaceuticals, etc., such as water, oily components, etc. Moisturizer, powder, pigment, emulsifier, solubilizer, gelling agent, cleaning agent, UV absorber, anti-inflammatory agent, thickener, pH adjuster, chelating agent, drug (medicinal component), fragrance, resin, Antibacterial and antifungal agents, antioxidants, alcohols and the like can be appropriately blended. Furthermore, other moisturizers, anti-aging agents, whitening agents, antioxidants and slimming agents, or various plants / fungi or extracts thereof can be used as long as the effects of the present invention are not impaired.
ムラサキ抽出物、カノコソウ抽出物から選択される１種又は２種の種々の組成物への配合量は、組成物の種類や目的等によって調整することができるが、効果や安定性などの点から、全量に対して、０．０００１〜１０．０質量％が好ましく、より好ましくは、０．００１〜５．０質量％であり、さらに好ましくは０．０１〜５．０質量％である。 The blending amount in one or two kinds of various compositions selected from Murasaki extract and valerian extract can be adjusted depending on the type and purpose of the composition, but from the point of effect and stability The amount is preferably 0.0001 to 10.0% by mass, more preferably 0.001 to 5.0% by mass, and still more preferably 0.01 to 5.0% by mass with respect to the total amount.
以下、実施例により本発明を具体的に説明するが、これにより本発明の範囲が限定されるものではない。 EXAMPLES Hereinafter, the present invention will be specifically described with reference to examples, but the scope of the present invention is not limited thereby.
［ムラサキ抽出物１］
ムラサキ（Lithospermum officinale）の根を乾燥後細切し、２０質量倍量のエタノール／ＢＧ混液（９：１）に浸漬し、ろ過後ろ液を採取し、溶媒を留去し、ムラサキ抽出物１とした。
[Murasaki extract 1]
The root of purple (Lithospermum officinale) is dried and then chopped, dipped in a 20-mass-fold ethanol / BG mixture (9: 1), the filtered solution is collected, the solvent is distilled off, and the purple extract 1 did.
［ムラサキ抽出物２］
ムラサキ抽出物１をグリセリン／エタノール混液（２５：７５）溶液にて１質量％濃度となるよう溶解後熟成し、再度ろ過したものをムラサキ抽出物２とした。
[Murasaki extract 2]
The Murasaki extract 1 was obtained by dissolving the Murasaki extract 1 in a glycerin / ethanol mixed solution (25:75) solution so as to have a concentration of 1% by mass, followed by aging and filtering again.
［カノコソウ抽出物１］
カノコソウの根及び根茎を乾燥後細切し、２０質量倍量の精製水に浸漬し、ろ過後ろ液を採取し、溶媒を留去し、カノコソウ抽出物１とした。
[Valerian extract 1]
The roots and rhizomes of valerian roots were dried and then chopped, soaked in 20 parts by mass of purified water, the filtrate after filtration was collected, the solvent was distilled off, and valerian extract 1 was obtained.
［カノコソウ抽出物２］
カノコソウ抽出物１を２０質量％１，３−ブチレングリコール水溶液溶解後熟成し、再度ろ過したものをカノコソウ抽出物２とした。
[Valerian extract 2]
The valerian extract 1 was aged after dissolving 20 mass% 1,3-butylene glycol aqueous solution and filtered again to obtain a valerian extract 2.
［表皮角化細胞賦活作用］
クラボウ社（倉敷紡績株式会社）製正常ヒト表皮角化細胞を、１ウェル当たり２．０×１０4個となるように９６ウェルマイクロプレートに播種した。播種培地には、市販のHumedia KG２（クラボウ社製）を用いた。２４時間培養後、各濃度となるように試料（抽出物）を添加したHumedia KG２に交換し、さらに２４時間培養した。上清を除いた後、３−（４，５−ジメチル−２−チアゾリル）−２，５−ジフェニルテトラゾリウムブロミド（ＭＴＴ）を１００μｇ／ｍＬ含有する培地に交換して約１時間培養した。その後、テトラゾリウム環の開環により生じるフォルマザンを２−プロパノールにて抽出し、マイクロプレートリーダーにて５５０ｎｍの吸光度を測定した。同時に、濁度として６５０ｎｍにおける吸光度を測定し、両測定値の差により細胞賦活作用を評価した。評価では、試料を含む培地の他に、コントロールとしてHumedia KG２を用いた。結果を表１、表２に示した。
[Epidermal keratinocyte activation]
Normal human epidermal keratinocytes manufactured by Kurabo Industries Co., Ltd. (Kurashiki Boseki Co., Ltd.) were seeded in a 96-well microplate so as to be 2.0 × 10 4 cells per well. As the seeding medium, commercially available Humedia KG2 (manufactured by Kurabo Industries) was used. After culturing for 24 hours, the medium was replaced with Humedia KG2 to which a sample (extract) was added so as to obtain each concentration, and further cultured for 24 hours. After removing the supernatant, the medium was exchanged with a medium containing 100 μg / mL of 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide (MTT) and cultured for about 1 hour. Thereafter, formazan produced by the opening of the tetrazolium ring was extracted with 2-propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values. In the evaluation, Humedia KG2 was used as a control in addition to the medium containing the sample. The results are shown in Tables 1 and 2.
表１、２に示した通り、ムラサキ抽出物１、カノコソウ抽出物１は、濃度依存的に表皮角化細胞の賦活作用が認められていた。 As shown in Tables 1 and 2, Murasaki extract 1 and valerian extract 1 were found to activate epidermal keratinocytes in a concentration-dependent manner.
［表皮細胞成長因子産生促進作用、表皮細胞成長因子受容体産生促進作用］
ヒト表皮角化細胞を５×105個/ウェルとなるように6ウェルプレートに播種し、Humedia KG2培地にて一晩培養した。植物抽出物を溶解した培地に交換し、37℃、５％ CO2インキュベーター内で24時間培養した。細胞からのTotal RNA抽出はTrizol reagentを用い、ライフテクノロジーズ社のプロトコールに従って調製した。cDNA合成後に下記のプライマーを使用してサイバーグリーン法によるリアルタイムPCRにより遺伝子発現を確認した。内部標準としてGAPDHを使用した。結果を表４に示す。
[Epidermal cell growth factor production promoting effect, epidermal growth factor receptor production promoting effect]
Human epidermal keratinocytes were seeded in a 6-well plate at 5 × 10 5 cells / well and cultured overnight in Humedia KG2 medium. The medium was replaced with a medium in which the plant extract was dissolved, and cultured in a 37 ° C., 5% CO 2 incubator for 24 hours. Total RNA extraction from cells was prepared using Trizol reagent according to the protocol of Life Technologies. After cDNA synthesis, gene expression was confirmed by real-time PCR by the cyber green method using the following primers. GAPDH was used as an internal standard. The results are shown in Table 4.
表４に示した通りムラサキ抽出物１、カノコソウ抽出物１は、高い表皮細胞成長因子産生促進作用、および表皮細胞成長因子受容体産生促進作用を示した。 As shown in Table 4, Murasaki extract 1 and valerian extract 1 showed high epidermal cell growth factor production promoting action and epidermal cell growth factor receptor production promoting action.
［実施例１］乳液
（１）スクワラン １０．０（質量％）
（２）メチルフェニルポリシロキサン ４．０
（３）水素添加パーム核油 ０．５
（４）水素添加大豆リン脂質 ０．１
（５）モノステアリン酸ポリオキシエチレン
ソルビタン（２０Ｅ．Ｏ．） １．３
（６）モノステアリン酸ソルビタン １．０
（７）グリセリン ４．０
（８）パラオキシ安息香酸メチル ０．１
（９）カルボキシビニルポリマー ０．１５
（１０）精製水 １００とする残部
（１１）アルギニン（１質量％水溶液） ２０．０
（１２）ムラサキ抽出物２ １．０
製法：（１）〜（６）の油相成分を８０℃にて加熱溶解する。一方（７）〜（１０）の水相成分を８０℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。冷却後４０℃にて、（１１）と（１２）を順次加え、均一に混合する。
[Example 1] Emulsion (1) Squalane 10.0 (mass%)
(2) Methylphenylpolysiloxane 4.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Polyoxyethylene monostearate
Sorbitan (20E.O.) 1.3
(6) Sorbitan monostearate 1.0
(7) Glycerin 4.0
(8) Methyl paraoxybenzoate 0.1
(9) Carboxyvinyl polymer 0.15
(10) Purified water 100 (11) Arginine (1% by weight aqueous solution) 20.0
(12) Murasaki Extract 2 1.0
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After cooling, (11) and (12) are sequentially added at 40 ° C. and mixed uniformly.
［実施例２］化粧水
（１）エタノール １５．０（質量％）
（２）ポリオキシエチレン（４０Ｅ．Ｏ．）硬化ヒマシ油 ０．３
（３）香料 ０．１
（４）精製水 １００とする残部
（５）クエン酸 ０．０２
（６）クエン酸ナトリウム ０．１
（７）グリセリン １．０
（８）ヒドロキシエチルセルロース ０．１
（９）カノコソウ抽出物２ １．０
製法：（１）に（２）および（３）を溶解する。さらに（４）〜（８）を順次添加した後、十分に攪拌し、（９）を加え、均一に混合する。
[Example 2] Lotion (1) Ethanol 15.0 (mass%)
(2) Polyoxyethylene (40E.O.) hydrogenated castor oil 0.3
(3) Fragrance 0.1
(4) Purified water 100 (5) Citric acid 0.02
(6) Sodium citrate 0.1
(7) Glycerin 1.0
(8) Hydroxyethyl cellulose 0.1
(9) Valerian extract 2 1.0
Production method: (2) and (3) are dissolved in (1). Further, after sequentially adding (4) to (8), the mixture is sufficiently stirred, and (9) is added and mixed uniformly.
［実施例３］クリーム
（１）スクワラン １０．０（質量％）
（２）ステアリン酸 ２．０
（３）水素添加パーム核油 ０．５
（４）水素添加大豆リン脂質 ０．１
（５）セタノール ３．６
（６）親油型モノステアリン酸グリセリン ２．０
（７）グリセリン １０．０
（８）パラオキシ安息香酸メチル ０．１
（９）アルギニン（２０質量％水溶液） １５．０
（１０）精製水 １００とする残部
（１１）カルボキシビニルポリマー（１質量％水溶液） １５．０
（１２）ムラサキ抽出物２ ０．５
製法：（１）〜（６）の油相成分を８０℃にて加熱溶解する。一方（７）〜（１０）の水相成分を８０℃にて加熱溶解する。これに前記油相成分を攪拌しながら加え、ホモジナイザーにより均一に乳化する。（１１）を添加して攪拌後、冷却し４０℃にて（１２）を加え、均一に混合する。
[Example 3] Cream (1) Squalane 10.0 (mass%)
(2) Stearic acid 2.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Cetanol 3.6
(6) Lipophilic glyceryl monostearate 2.0
(7) Glycerin 10.0
(8) Methyl paraoxybenzoate 0.1
(9) Arginine (20 mass% aqueous solution) 15.0
(10) Remainder 100 (11) Carboxyvinyl polymer (1% by weight aqueous solution) 15.0
(12) Murasaki extract 2 0.5
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. (11) is added and stirred, then cooled and (12) is added at 40 ° C. and mixed uniformly.
［実施例４］美容液
（１）精製水 １００とする残部（質量％）
（２）グリセリン １０．０
（３）ショ糖脂肪酸エステル １．３
（４）カルボキシビニルポリマー（１質量％水溶液） １７．５
（５）アルギン酸ナトリウム（１質量％水溶液） １５．０
（６）モノラウリン酸ポリグリセリル １．０
（７）マカデミアナッツ油脂肪酸フィトステリル ３．０
（８）Ｎ−ラウロイル−Ｌ−グルタミン酸
ジ（フィトステリル−２−オクチルドデシル） ２．０
（９）硬化パーム油 ２．０
（１０）スクワラン（オリーブ由来） １．０
（１１）ベヘニルアルコール ０．７５
（１２）ミツロウ １．０
（１３）ホホバ油 １．０
（１４）１，３−ブチレングリコール １０．０
（１５）Ｌ−アルギニン（１０質量％水溶液） ２．０
（１６）カノコソウ抽出物２ ０．３
製法：（１）〜（６）の水相成分を混合し、７５℃にて加熱溶解する。一方、（７）〜（１４）の油相成分を混合し、７５℃にて加熱溶解する。次いで、上記水相成分に油相成分を添加して予備乳化を行った後、ホモミキサーにて均一に乳化する。冷却後５０℃にて（１５）を、４０℃にて（１６）を加え、均一に混合する。
[Example 4] Cosmetic liquid (1) The balance (mass%) of purified water 100
(2) Glycerin 10.0
(3) Sucrose fatty acid ester 1.3
(4) Carboxyvinyl polymer (1% by weight aqueous solution) 17.5
(5) Sodium alginate (1% by weight aqueous solution) 15.0
(6) Polyglyceryl monolaurate 1.0
(7) Macadamia nut oil fatty acid phytosteryl 3.0
(8) N-lauroyl-L-glutamic acid di (phytosteryl-2-octyldodecyl) 2.0
(9) Hardened palm oil 2.0
(10) Squalane (derived from olive) 1.0
(11) Behenyl alcohol 0.75
(12) Beeswax 1.0
(13) Jojoba oil 1.0
(14) 1,3-butylene glycol 10.0
(15) L-arginine (10% by mass aqueous solution) 2.0
(16) Valerian extract 2 0.3
Production method: The aqueous phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C. Next, the oil phase component is added to the aqueous phase component and preliminary emulsification is performed, followed by uniform emulsification with a homomixer. After cooling, add (15) at 50 ° C. and (16) at 40 ° C. and mix uniformly.
［実施例５］水性ジェル
（１）カルボキシビニルポリマー ０．５（質量％）
（２）精製水 １００とする残部
（３）水酸化ナトリウム（１０質量％水溶液） ０．５
（４）グリセリン １０．０
（５）１，３−ブチレングリコール １０．０
（６）エタノール １０．０
（７）パラオキシ安息香酸メチル ０．１
（８）香料 ０．１
（９）ムラサキ抽出物２ ０．３
（１０）カノコソウ抽出物２ ０．３
（１１）ポリオキシエチレン（６０Ｅ．Ｏ．）硬化ヒマシ油 １．０
製法：（１）を（２）に加え、均一に攪拌した後、（３）を加える。均一に攪拌した後、（４）に予め溶解した（５）を加える。均一に攪拌した後、予め混合しておいた（６）〜（１１）を加え、均一に攪拌混合する。
[Example 5] Aqueous gel (1) Carboxyvinyl polymer 0.5 (mass%)
(2) The balance made into purified water 100 (3) Sodium hydroxide (10 mass% aqueous solution) 0.5
(4) Glycerin 10.0
(5) 1,3-butylene glycol 10.0
(6) Ethanol 10.0
(7) Methyl paraoxybenzoate 0.1
(8) Fragrance 0.1
(9) Murasaki extract 2 0.3
(10) Valerian extract 2 0.3
(11) Polyoxyethylene (60E.O.) hydrogenated castor oil 1.0
Manufacturing method: (1) is added to (2), and after stirring uniformly, (3) is added. After stirring uniformly, (5) previously dissolved in (4) is added. After stirring uniformly, the previously mixed (6) to (11) are added and stirred and mixed uniformly.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016213669A JP7246125B2 (en) | 2016-10-31 | 2016-10-31 | Epidermal cell activator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016213669A JP7246125B2 (en) | 2016-10-31 | 2016-10-31 | Epidermal cell activator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018070524A true JP2018070524A (en) | 2018-05-10 |
| JP7246125B2 JP7246125B2 (en) | 2023-03-27 |
Family
ID=62113846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016213669A Active JP7246125B2 (en) | 2016-10-31 | 2016-10-31 | Epidermal cell activator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7246125B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020015668A (en) * | 2018-07-23 | 2020-01-30 | 株式会社ノエビア | Skin composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019709A (en) * | 1983-07-14 | 1985-01-31 | Tsunetaka Yokoyama | Preparation of cosmetic for preventing aging of skin and promoting cell division |
| JPH09315930A (en) * | 1996-05-28 | 1997-12-09 | Kanebo Ltd | Cosmetic material for skin |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003335619A (en) | 2002-05-14 | 2003-11-25 | Noevir Co Ltd | Skin care preparation for external use |
| JP6019709B2 (en) | 2012-04-25 | 2016-11-02 | ブラザー工業株式会社 | Developer container |
-
2016
- 2016-10-31 JP JP2016213669A patent/JP7246125B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019709A (en) * | 1983-07-14 | 1985-01-31 | Tsunetaka Yokoyama | Preparation of cosmetic for preventing aging of skin and promoting cell division |
| JPH09315930A (en) * | 1996-05-28 | 1997-12-09 | Kanebo Ltd | Cosmetic material for skin |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020015668A (en) * | 2018-07-23 | 2020-01-30 | 株式会社ノエビア | Skin composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7246125B2 (en) | 2023-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4299374B2 (en) | Cell activator and its application | |
| JP2015027998A (en) | Moisturizer, skin barrier function activator, tight junction formation accelerator, trpv4 expression enhancer, intracellular calcium concentration increaser, intracellular calcium concentration increaser, lipid synthesis accelerator, blood flow improver and periocular darkness ameliorator | |
| JP2009242311A (en) | Scf secretion inhibitor and skin care preparation for external use for making skin pore inconspicuous | |
| JP4869469B2 (en) | Melanin production promoter and gray hair improving agent | |
| JP4460420B2 (en) | Collagen production promoter | |
| JP6377879B1 (en) | Topical skin preparation | |
| JP2008303147A (en) | External preparation for skin | |
| JP2001114636A (en) | Hyaluronic acid production and catalase production promoting agent, fibroblast activating agent and skin lotion | |
| JP2012051837A (en) | Glutathione production promoter | |
| JP7246125B2 (en) | Epidermal cell activator | |
| WO2014010657A1 (en) | Processed nutmeg product and method for producing same | |
| JP6723979B2 (en) | Wrinkle improver | |
| JP4083111B2 (en) | β-endorphin production promoter | |
| JP2011246354A (en) | Skin external preparation | |
| JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
| JP3754025B2 (en) | Cell activator, antioxidant, and skin external preparation | |
| JP7485336B2 (en) | MSX-2 mRNA expression promoter, eyelash growth agent, and external preparation composition for eyelash growth | |
| JP6786193B1 (en) | Extracellular ATP concentration increase inhibitor | |
| JP6285598B1 (en) | Collagen production promoter, heat shock protein production promoter, decorin production promoter | |
| JP5946698B2 (en) | Whitening agent and skin cosmetics | |
| JP5144048B2 (en) | Radical scavenger, antioxidant skin external preparation, and radical scavenging method | |
| JP2008013522A (en) | Cell growth promoter | |
| JP4994684B2 (en) | Moisturizer, cell activator, and antioxidant | |
| JP4520349B2 (en) | Cell activator and skin external preparation using the same | |
| JP2004137166A (en) | Skin care preparation for external use, cell activator and antioxidant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190712 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200824 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210107 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210406 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220614 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220906 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20221108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230110 |
|
| C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20230214 |
|
| C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20230314 |
|
| C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20230314 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230314 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7246125 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |